Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Stress and the risk of multiple sclerosis.
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Centocor briefing document for Ustekinumab, submitted to FDA
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Sex-related factors in multiple sclerosis susceptibility and progression.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Laquinimod for multiple sclerosis.
Shorter washout reduces MS relapse switching off natalizumab
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
[Infections and fingolimod].
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Poor sleep in patients with multiple sclerosis.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.

Pages